Last reviewed · How we verify
PF-07265807 (pf-07265807)
PF-07265807 (generic name: pf-07265807) is a Given 2 weeks on/1 week off drug developed by Pfizer Inc.. It is currently in discontinued development.
Given 2 weeks on/1 week off
PF-07265807 is being studied in a clinical trial for the treatment of metastatic solid tumors. The trial, NCT04458259, is a phase 1 study that also involves the interventions Sasanlimab and Axitinib.
At a glance
| Generic name | pf-07265807 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Given 2 weeks on/1 week off |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
PF-07265807 works by inhibiting a particular enzyme or protein involved in immune cell activation and communication. When the immune system overreacts in certain conditions, these proteins become hyperactive, triggering excessive inflammation. By selectively blocking this target, the drug helps calm the immune response without completely shutting down the body's ability to fight infections and defend itself. The selective nature of this approach is important because it focuses on the specific pathway driving the disease rather than broadly suppressing the entire immune system. This targeted strategy can help reduce disease symptoms and progression while potentially lowering the risk of serious side effects associated with more general immunosuppression. PF-07265807 represents a precision medicine approach where the drug is designed to interrupt a particular molecular communication chain in immune cells. By doing so, it addresses the root cause of inflammation in the targeted condition, allowing patients to achieve disease control with a mechanism that's tailored to the specific biology of their disease.
Approved indications
Pipeline indications
- Neoplasm Metastasis — discontinued
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07265807 CI brief — competitive landscape report
- PF-07265807 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about PF-07265807
What is PF-07265807?
How does PF-07265807 work?
Who makes PF-07265807?
What is the generic name of PF-07265807?
What drug class is PF-07265807 in?
What development phase is PF-07265807 in?
Related
- Drug class: All Given 2 weeks on/1 week off drugs
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing